Study of Resistance Mutations to Dolutegravir in Adults with HIV Treated in Chokwe9, Mozambique

What this Trial Is About

Researchers are studying people living with HIV in Mozambique to understand if the virus develops resistance to antiretroviral drugs when the infection is not fully controlled despite treatment. This observational study focuses on patients receiving a common first-line treatment called TLD but who still have detectable virus levels. The goal is to see if the virus mutates in ways that make controlling HIV infection more difficult. During one study visit, participants will have a blood sample taken to test for mutations in the HIV virus that might resist antiretroviral drugs. The study uses advanced genetic testing techniques to analyze the virus, including RNA extraction, gene amplification, and sequencing. Along with the blood test, researchers will collect routine clinical and demographic information and record medical history related to HIV infection and treatment. Participants will provide information through a questionnaire during the visit, and their blood samples will be analyzed for drug resistance mutations. The researchers will measure the selection of resistance mutations to dolutegravir and other drugs over three months. The study involves a single visit and includes safety and laboratory assessments but does not involve any changes in treatment. Participation lasts only for this one visit, and results will help understand virus behavior under current treatment conditions.

Selection of Resistant Mutations to Dolutegravir in PLWH Treated in Mozambique